Joanne Lin is a distinguished Sr. Principal Biologist at Eli Lilly and Company, where she leverages over 15 years of extensive experience in drug discovery and biomolecular interactions. Her expertise lies in Large Biomolecular Interactions Binding Analysis, utilizing advanced techniques such as Surface Plasmon Resonance...
Joanne Lin is a distinguished Sr. Principal Biologist at Eli Lilly and Company, where she leverages over 15 years of extensive experience in drug discovery and biomolecular interactions. Her expertise lies in Large Biomolecular Interactions Binding Analysis, utilizing advanced techniques such as Surface Plasmon Resonance (SPR) and BIAcore, as well as KinExA for precise drug candidate evaluation. Joanne has a proven track record in lead identification and selection, where her in-depth binding characterization has been pivotal in advancing therapeutic candidates through the drug development pipeline.
In her current role, Joanne is instrumental in developing and optimizing affinity and binding assays across various platforms, including protein/antibody interactions, membrane-bound targets, and cell binding assays. Her proficiency in automation technologies enhances the efficiency and reproducibility of these assays, ensuring that Eli Lilly remains at the forefront of biopharmaceutical innovation. Joanne's skill set is further complemented by her experience with high-performance liquid chromatography (HPLC), protein purification, and enzyme-linked immunosorbent assays (ELISA), which are critical in the characterization of biologics.
Joanne's previous role as a Consultant Biologist allowed her to refine her skills in immunogenicity assessment, where she contributed to the understanding of immune responses to therapeutic proteins. Her adeptness in immunocytochemistry and flow cytometry has enabled her to provide valuable insights into cellular interactions and responses, further enriching her contributions to the biotechnology industry. With a commitment to scientific excellence and a passion for advancing drug discovery, Joanne Lin continues to make significant strides in her field, driving innovation at Eli Lilly and Company.
